Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19
Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19
复制标题
DOI：
10.1007/s40267-020-00750-w
复制
发表时间：
2020-08-01
影响因子：
--
通讯作者：
Zaidi, Sabeen Khurshid
中科院分区：
文献类型：
--
作者：
Khan, Sikandar Hayat;Zaidi, Sabeen Khurshid
COVID-19 最近已成为一种具有相关社会经济影响的重大流行病。死亡率统计数据表明，COVID-19 对于患有高血压等合并症的老年患者更具致命性。关于使用血管紧张素转换酶 (ACE) 抑制剂 (ACEi) 和血管紧张素受体阻滞剂 (ARB) 对 COVID-19 患者是否有用或有害的争论一直存在，这两种说法都得到了具有不同假设的研究人员的支持。支持使用这些药物的研究人员认为 ACE2 功能阻滞剂可以阻止 SARS-CoV-2 病毒进入细胞，从而改善患者的治疗效果。相反的观点认为，持续使用这些药物会导致呼吸道上皮上 ACE2 受体过度表达，从而使 SARS-CoV-2 更容易进入细胞内，从而增强病毒复制和组织损伤。这篇简短的评论讨论了该主题的现有研究，目的是整合数据，以便就其使用或其他方面提出建议。此外，作者还建议了该主题的未来研究领域。
COVID-19 has recently become a major pandemic with associated socioeconomic dimensions. Mortality statistics suggest that COVID-19 is more lethal in aged patients with comorbid conditions including hypertension. There is ongoing debate about whether the use of angiotensin converting enzyme (ACE) inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are useful or hazardous in patients with COVID-19, with both narratives supported by researchers with different hypotheses. The researchers supporting the use of these medications believe ACE2 functional blockers may block cellular entry of the SARS-CoV-2 virus and thus improve patient outcomes. The counter viewpoint argues that continuous use of these drugs results in hyperexpression of ACE2 receptors on respiratory epithelium allowing easier SARS-CoV-2 intracellular entry, resulting in enhanced viral replication and tissue damage. This short review discusses the available research on the subject with the objective to consolidate data to allow formulation of recommendations on their use or otherwise. Moreover, the authors also suggest areas for future research on the subject.